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ABSTRACT 
 
Objectives: To review systematically completed trial evidence assessing hormone replacement therapy 
(HRT) to subsequent stroke risk, in particular assessing stroke by pathological type, severity and outcome. 
Data sources: Randomised controlled trials of HRT were identified from the Cochrane Library, reviews and 
reference lists of relevant papers. 
Review methods: Rates for cerebrovascular events were extracted, combined and analysed using a random 
effects model. Sensitivity analyses were defined to explain any heterogeneity, including phase of prevention 
(primary, secondary), type of HRT (mono/unopposed oestrogen, dual/opposed), type of oestrogen (estradiol, 
conjugated equine oestrogen), size of trial (<5000, >5000 patients), length of follow-up (≤3 years, >3 years), 
and gender. 
Results: Fourteen trials (t), involving 34,976 subjects, were identified. HRT was associated with significant 
increases in total stroke, odds ratio (95% confidence intervals) 1.29 (1.12-1.47, t=14), non-fatal stroke 1.23 
(1.06-1.44, t=11) stroke leading to death or disability/dependency 1.56 (1.11-2.20, t=4), ischaemic stroke 
1.28 (1.06-1.56, t=5), and a trend to more fatal stroke 1.28 (0.87-1.88, t=12). HRT was not associated with 
haemorrhagic stroke 1.06 (0.64-1.75, t=5), or transient ischaemic attack 1.00 (0.75-1.33, t=6). No 
heterogeneity was present in any analysis. 
Conclusions: HRT is associated with an increased risk of stroke, particularly of ischaemic type. Subjects 
having a stroke on HRT appear to have a worse outcome. HRT cannot be recommended for the prevention of 
stroke. 
 
3 
INTRODUCTION 
 
Sex steroid hormones are believed to provide women with endogenous protection against cerebrovascular 
events. Pre-menopausal women have a lower risk of stroke relative to men of the same age 
1 2
 whilst the 
incidence of stroke increases rapidly following the menopause, 
3
 coincident with diminished circulating 
levels of oestrogen and progesterone. As a result, hormone replacement therapy (HRT) has been used widely 
for vascular prophylaxis in parallel with its known effects in reducing menopausal symptoms and bone loss. 
Longitudinal observational studies have suggested that HRT may reduce cardiovascular and cerebrovascular 
disease. 
4
 However, a review of these studies (which also included two randomised trials) found that the 
number of strokes was increased. 
5
 Furthermore, the results of randomised controlled trials (RCT) have given 
conflicting results with studies either finding no benefit or even apparent hazard. A recent non-systematic 
review of RCTs found that treatment with HRT was associated with an increased risk of stroke. 
6
 
 
The aim of this study was to review systematically completed trial evidence relating HRT to subsequent 
stroke risk, in particular assessing stroke by pathological type, severity and outcome. 
4 
METHODS 
 
Searching 
Publications were identified from searches of The Cochrane Library, Embase and Medline (from 1966 to 
May 2004), in addition the reference lists of previous reviews 
7-9
 and reference the identified articles were 
made.  
 
Selection 
All completed and published randomised controlled trials of HRT against a control group reporting stroke 
events were included. Publications not reported in English or where event numbers were given for stroke or 
transient ischaemic attack and not separately were excluded.  Trials were found which included both males 
and females, and in one case males exclusively. It was decided to include both genders in the review but to 
analyse those trials which included males separately to those which included females only. From the search 
18 trials were identified, of which fourteen met our criteria for inclusion. Four trials did not meet our 
inclusion criteria (table 1).  
 
Quality assessment 
Studies were assessed in five areas, including method of randomisation, blinding, reporting of withdrawals, 
generation of random numbers and allocation concealment. Trials scored one point for each area addressed, 
therefore receiving a score between 0-5, with 5 reflecting the highest level of quality. 
10
  
 
Data abstraction 
All data were independently extracted by the two authors (LG and PB). Disparities were resolved by 
consensus.  
 
Study characteristics 
Information on trial size, treatment regimen (oestrogen + progesterone), length of follow-up and outcome 
were recorded. Outcomes included stroke events (fatal and non fatal), type of stroke (ischaemic, 
haemorrhagic, not known), functional outcome (combined death and disability/dependency), and case 
fatality. Where available, data were also collected on the number of transient ischaemic attacks, but these 
were not included in the overall stroke outcome. Where obtainable, data related to intention-to-treat analyses. 
 
Quantitative data synthesis 
Data were analysed using Stata (version 7) and Cochrane Review Manager (version 4). The effect of HRT on 
dichotomous outcomes was assessed using the odds ratio calculated using a random effects model since the 
trials were expected to be heterogeneous. Pre-specified sensitivity analyses were defined to explain any 
heterogeneity, including phase of prevention (primary, secondary), type of HRT (mono/unopposed 
oestrogen, dual/opposed), type of oestrogen (estradiol, conjugated equine oestrogen), size of trial (<5000, 
5 
>5000 patients), length of follow-up (≤3 years, >3 years), gender (females only) and quality (those scoring 
5/5 only). Interactions between subgroups and treatment were assessed. Publication bias was examined using 
Eggers test.
11
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RESULTS 
 
Study characteristics 
Fourteen trials were identified for inclusion involving 34,976 subjects (table 1, figure 1). The trials varied in 
size between 134 
12
 and 16,608. 
13
  The trials included four investigating primary vascular prevention 
13-16
 
and nine in patients with prior vascular events: stroke 
17-19
, ischaemic heart disease 
20-23
 and venous 
thromboembolism. 
24
 The average age of the patients varied between 55 and 71; three trials not only included 
post menopausal women but also included men, with one trial including men exclusively. 
12 18 19
 Two trials 
required that women should not have had a hysterectomy.
13 21
 Follow-up varied between 0.9 and 6.8 years. 
Mono-HRT (oestrogen alone) was studied in seven trials and dual (or opposed) HRT in the others. Both 
mono and dual comparison arms of the ‘Women’s Health Initiative Trial’ were terminated prematurely due 
to HRT treatment being associated with hazard.
13 15
 All trials, apart from two 
23 25
, were placebo controlled. 
 
Data quality 
 
 
Quantitative data synthesis 
Stroke occurred in 2.3% of the participants randomised to no HRT and was significantly increased by one-
third in those randomised to HRT (figure 2). This increase in stroke resulted from excess ischaemic strokes 
but not primary intracerebral haemorrhage, as also seen in WHI dual alone.
13
 An early increase in stroke 
occurred during the first 6 months of treatment in the WEST trial of secondary stroke prevention,
17
 
analogous to the early increase in CHD events seen in the HERS trial of secondary CHD prevention.
21
 
 
A poor outcome after stroke, judged as combined death and dependency, was increased by half with HRT; a 
non-significant increase in fatal stroke was also seen. This relationship between HRT and severe stroke was 
present individually in three trials – HERS, WEST, WHI dual (figure 3).
13 21 26
 HRT did not alter the rate of 
transient ischaemic attack (table 2). No statistical heterogeneity was seen for any of the stroke outcomes. 
 
Pulmonary embolism was increased by three-quarters in those randomised to HRT (table 2). In contrast, 
CHD events were not more frequent with HRT. No statistical heterogeneity was observed for either PE or 
CHD. 
 
Sensitivity analyses were performed on several prognostic factors for the total stroke outcome (table 3). The 
results of these analyses appear to be driven by the large WHI dual study and significant results are seen for 
the sub groups which contain this study. However, significant heterogeneity was not present between trials 
examining primary versus secondary prevention, mono versus dual HRT, CEE versus estradiol, shorter 
versus longer follow-up, smaller versus larger trials, and those including women and men versus women 
alone. No significant publication bias was found for the all stroke outcome (Eggers test p=0.24). 
7 
DISCUSSION 
 
This systematic review supports the results of individual trials and previous reviews finding that HRT does 
not reduce the risk of stroke in post-menopausal women. Indeed, HRT was associated with an overall 
increase in the risk of stroke of 27%. This effect was driven by an increase in ischaemic but not 
haemorrhagic stroke. Importantly, the severity of stroke was increased since the frequency of a poor 
functional outcome, judged as combined death and disability/dependency, was 56% higher in those 
randomised to HRT. Similarly, fatal stroke was non-significantly increased. 
 
Why HRT should increase ischaemic stroke and its severity when biological plausibility and previous 
observational studies suggested it might protect against cerebrovascular events remains unclear. This 
discrepancy between observational and intervention studies is not unique; for example, whilst antioxidant 
vitamins might on biological grounds have been expected to protect against vascular disease with 
observational studies supporting this hypothesis, several large RCTs involving antioxidant vitamins found no 
beneficial effect.
27
 A number of possible explanations exist for why HRT promoted stroke. First, it is 
possible that the results of the RCTs are wrong although this is unlikely since none of the studies were 
positive, i.e. HRT did not reduce stroke in any study, with 11 trials being neutral and 3 negative. The absence 
of a beneficial effect on stroke was mirrored for VTE and CHD. If the trials are correct then the 
observational studies must have been falsely positive. Second, the trials involved either mono or dual HRT. 
Whilst long-term unopposed oestrogen therapy can promote cause uterine cancer, this would not explain an 
increase in stroke. In contrast, adding a progestogen could have had detrimental effects since this class of 
drugs can promote atherogenesis and vasoconstriction.
28
 This is particularly true for medroxyprogesterone 
acetate which was used in most of the trials involving dual HRT. Nevertheless, no heterogeneity between 
trials of mono and dual HRT was present suggesting that oestrogen itself, given as oestradiol or CEE, might 
be the culprit. Third, within-class differences in HRT may mean that the most appropriate type of oestrogen 
has yet to be tested adequately; the RCTs assessed either conjugated equine oestrogens or estradiol but not 
other types such as phytoestrogen.
29
 However, there was no evidence for statistical heterogeneity between 
the trials with respect to type of oestrogen. 
 
Fourth, the dose of oestrogen (and progestogen if present) may have been too high. The usually starting dose 
of CEE and estradiol in the UK in older women are 0.625 mg and 1 mg respectively, although the dose may 
then be titrated up if menopausal vasomotor symptoms persist. These doses are below those used in several 
of the trials. Fifth, the delivery route may be important since important pharmacological differences exist 
between oral and transdermal administration of oestrogen, especially relating to first pass liver metabolism. 
Sixth, several of the trials may have been too short with a median length of less than 3 years contrasting with 
the earlier observational studies. Of note, both HERS and WEST found an early vascular hazard which 
disappeared later.
21 26
 The hazard during the first year of treatment appears to reflect the development of a 
thrombophilic state which may not persist. This raises the possibility that an extended follow-up would have 
8 
revealed long term benefit. An analogous situation exists with statin therapy whereby benefit was found in 
trials with longer rather than shorter follow-up.
30
 Nevertheless, the largest two of the HRT trials, WHI dual 
and WHI mono, had follow-up for more than 5 years and yet found no beneficial effect on stroke risk. 
 
In summary we have found that the use of HRT is associated with an increased risk of stroke, typically 
ischaemic in type and severe in nature. HRT cannot be recommended for the primary or secondary 
prevention of stroke. Extrapolation of the data suggest that patients at high risk of stroke, e.g. those with 
previous stroke, coronary heart disease, or multiple vascular risk factors, should cease taking it unless there 
is a strong contrary medical reason. 
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TABLE 1  
Randomised controlled trials excluded from the review 
Trial & year Indication Subjects Intervention 
(daily dose) 
Reason for exclusion 
WISDOM 
31
 Healthy 5,664 CEE + MPA  
CEE 
Trial completed but not reported at time of writing 
De Kleijn  et 
al, 1999 
32
 
Healthy 121 E2 (1.5 mg) +DG (0.15 mg), or 
CEE (0.625 mg) + N (0.15 mg) 
No stroke events reported 
Herrington et 
al, 2000 
33
 
Coronary disease 309 CEE (0.625 mg), or CEE (0.625 mg + MPA (2.5 mg) Numbers only given for stroke or TIA and not 
separately 
Clarke et al, 
2002 
34
 
IHD 255 E2 (2.5 mg) or E2 (3 mg) + NG (4 mg) Numbers only given for stroke or TIA and not 
separately  
12 
TABLE 1 
 
Randomised controlled trials of hormone replacement therapy in the primary and secondary prevention of vascular disease included in the meta analysis. 
 
Trial & year Indication Subjects Age 
(years) 
Female 
(%) 
Ethnicity 
white (%) 
Uterus 
present 
(%) 
Follow-up 
(years) 
Stroke rate 
(control group, 
%/year) 
Intervention 
(daily dose) 
Compliance 
(%) 
Quality  
score  
(0-5) 
Marmorston, 
1965 
19
 
Cerebral 
thrombosis 
200 62.1 37 ? ? ? ? Females: CEE 
(0.625mg) Males: 
CEE (0.625-2.5 
mg) 
? 2 
Veterans 
Administration 
Cooperative,  
1966 
18
 
Cerebrovasc
ular disease 
592 ? 0 79.2 ? 1.4 7.72 CEE (1.25 mg) 
after 1 year CEE 
(2.5 mg) 
94 5 
McDowell et 
al, 1967 
12
 
Non-
embolic 
cerebral 
infarction 
134 64 25 ? ? Treated 0.9, 
control 1.2 
0 CEE (1.25mg) 84 3 
PEPI Writing 
Group, 1995 
14
 
Healthy 875 56 100 ? 68 3 0 CEE 
+ MPA or MP 
76 5 
Simon et al,  
1998 
21
 
IHD 2,763 67 100 ? 100 4.1 1.18 CEE (0.625 mg) 
+ MPA (2.5 mg) 
78 5 
Høibraaten et 
al, 2000 
24
 
VTE 140 56 100 ? ? 1.3 1.11 E2 (2mg) 
+ NTA (1mg) 
76 5 
Hodies et al,  
2001 
16
 
Healthy 222 62 100 58 62 2.0 0 E2 (1 mg) 94 5 
Angerer et al,  
2001 
23
 
Carotid 
athero 
264 ? 100 ? ? 1 0 E2 (1 mg) 
+ GG (0.025 mg) 
98 4 
Viscoli et al, 
2001 
26
 
Stroke 664 71 100 ? 55 2.7 6.34 E2 (1 mg) 66 5 
The ESPRIT 
team, 2002 
20
 
MI 1,017 62.3/6
2.9 
100 ? ? 2.0 0.59 E2 (2 mg) 53 5 
Waters et al,  
2002 
22
 
IHD 423 65 100 ? 41 2.8 0.67 CEE (0.625 mg) 
+ MPA (2.5 mg) † 
69 5 
Wassertheil-
Smoller et al, 
Healthy 16,608 63 100 84 100 5.6 0.24 CEE (0.625 mg) 
+ MPA (2.5 mg) 
60 5 
13 
2003 
13
 
Holmberg et al,  
2004 
25
 
Breast 
cancer 
345 55 100 ? ? 2.1 0 No specified 
treatment  
? 3 
WHI Steering 
Committee,  
2004 
15
 
Healthy 10,739 63.6 100 75.3 0 6.8 0.32 CEE (0.625 mg) 46.2 5 
CEE, ‘conjugated equine estrogen’; DG: desogestrel; E2, 17ß-estradiol; GG: gestogene; IHD: ischaemic heart disease; MI: myocardial infarction; MPA: 
medroxyprogesterone acetate; NG: norgestrel; NTA: northisterone acetate; VTE: venous thromboembolic. † progesterone given if no hysterectomy 
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TABLE 2 
 
Effect of hormone replacement therapy on stroke, its type and outcome. Odds ratio (95% confidence intervals) using random effects model, and heterogeneity 
 
 Trials Subjects Events Control event 
rate (%) 
Odds ratio 
(95% CI) 
p Heterogeneity 
p 
Stroke, all 14 34,976 916 2.32 1.29 (1.12 – 1.47) 0.0003 0.46 
   Ischaemic 5 20,510 442 1.91 1.28 (1.06 -1.56) 0.01 0.46 
   Haemorrhagic 5 20,510 63 0.30 1.06 (0.64 -1.75) 0.82 0.56 
Transient ischaemic 
attack 
6 5,451 203 4.08 1.00 (0.75 – 1.33) 1.00 0.71 
Outcome        
   Fatal 12 33,718 129 0.33 1.28 (0.87 – 1.88) 0.21 0.39 
   Non-fatal 11 33,518 710 1.93 1.23 (1.06 – 1.44) 0.007 0.45 
   Death or dependency 4 17,733 145 0.65 1.56 (1.11 – 2.20) 0.01 0.93 
 
15 
TABLE 3 
 
Sensitivity analyses of the effect of hormone replacement therapy on total stroke 
 
 Trials Subjects Control event  
Rate % 
Odds ratio 
(95% CI) 
χ
2 
Interactio
n 
Stroke, all 14 34976 2.32 1.29 (1.12 – 1.47)  
Prevention     0.32 
   Primary 5 28789 1.61 1.36 (1.14 – 1.61)  
   Secondary 9 6187 5.59 1.17 (0.90 – 1.52)  
HRT     0.75 
   Oestrogen alone 7 13558 3.18 1.20 (0.90 – 1.62)  
   Oestrogen & progesterone 7 21418 1.75 1.31 (1.08 – 1.60)  
Type of oestrogen †     0.59 
   Estradiol 5 2307 5.71 1.15 (0.80 – 1.65)  
   Conjugated equine oestrogens 8 32669 2.09 1.29 (1.06 – 1.55)  
Trial size     0.31 
   Small (<5000) 12 7629 4.87 1.17 (0.94 – 1.44)  
   Large (>5000) 2 27347 1.66 1.36 (1.14 – 1.61)  
Length of follow-up     0.35 
   Shorter, <3 years 11 4866 4.88 1.14 (0.83 – 1.56)  
   Longer, >3 years 3 30110 1.96 1.33 (1.14 – 1.55)  
Gender     - 
   Females only ‡ 12 34133 2.18 1.30 (1.13 – 1.50)  
16 
Quality      
  Score of 5 only 10   1.28 (1.12 – 1.46)  
  Score 0-4 4   2.11 (0.14 – 32.18)  
 
† Habits 
25
 not included as type of oestrogen left to investigators judgement 
‡ Including women only from Marmorston 
19
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FIGURE 1 
 
Flow diagram of search strategy 
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FIGURE 2 
 
Forrest plot of randomised controlled trials of hormone replacement therapy in the primary and secondary 
prevention of stroke, coronary heart disease and pulmonary embolism 
 
 
 
 
